Comparative Pharmacology
Head-to-head clinical analysis: FERABRIGHT versus FERAHEME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERABRIGHT versus FERAHEME.
FERABRIGHT vs FERAHEME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron replacement therapy: provides elemental iron for erythropoiesis, correcting iron deficiency anemia.
Ferumoxytol is a superparamagnetic iron oxide nanoparticle coated with a semisynthetic carbohydrate shell. It serves as a source of iron for hemoglobin synthesis and replenishes iron stores. The iron core is processed intracellularly to release iron, which is then incorporated into hemoglobin or stored as ferritin. The carbohydrate shell is metabolized and eliminated.
Intravenous bolus of 100 mg ferric carboxymaltose (elemental iron), administered no more than 3 times per week until iron repletion is achieved.
510 mg intravenously once, followed by a second 510 mg dose 3 to 8 days later, not exceeding 1020 mg per course.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours in adults with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Terminal half-life of ferumoxytol (iron core) is approximately 14-21 hours; for the intact nanoparticle (carbohydrate shell), half-life is about 15 hours. Clinically, iron is continuously released and incorporated, extending effects beyond half-life.
Renal elimination of unchanged drug accounts for approximately 60-70% of total clearance, with biliary/fecal excretion contributing 20-30%. The remainder undergoes hepatic metabolism.
Renal: minimal (<1% as intact drug); primarily degraded endogenously with iron incorporated into hemoglobin; fecal/biliary elimination of unabsorbed iron is negligible.
Category C
Category C
Iron Supplement
Iron Supplement